TACE-dependent TGFα shedding drives triple-negative breast cancer cell invasion

International Journal of Cancer

Volumn 133, Issue 11, 2013, Pages 2587-2595

  Giricz, Orsi ^a   Calvo, Veronica ^a   Peterson, Esther A ^a   Abouzeid, Christiane M ^b   Kenny, Paraic A ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

epidermal growth factor receptor; TACE ADAM17; transforming growth factor alpha; triple negative breast cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL INVASION; CELL MIGRATION; COLONY FORMATION; CONTROLLED STUDY; ENZYME ACTIVITY; GENE EXPRESSION PROFILING; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; TUMOR CLASSIFICATION;

EPIDERMAL GROWTH FACTOR RECEPTOR; TACE/ADAM17; TRANSFORMING GROWTH FACTOR ALPHA; TRIPLE-NEGATIVE BREAST CANCER;

ADAM PROTEINS; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MUTATION; NEOPLASM INVASIVENESS; NEOPLASMS; PHOSPHORYLATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR ALPHA;

EID: 84884909066     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28295     Document Type: Article

References (33)

1. Foulkes WD, Smith IE, Reis-Filho JS,. Triple-negative breast cancer. N Engl J Med 2010; 363: 1938-48.
2. Carlson RW, Allred DC, Anderson BO, et al. Breast cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 2009; 7: 122-92.
3. Eccles SA,. The epidermal growth factor receptor/Erb-B/HER family in normal and malignant breast biology. Int J Dev Biol 2011; 55: 685-96.
4. Yarden Y, Sliwkowski MX,. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2: 127-37.
5. Kenny PA. TACE,: a new target in epidermal growth factor receptor dependent tumors. Differentiation 2007; 75: 800-8.
6. Harris RC, Chung E, Coffey RJ. EGF, receptor ligands. Exp Cell Res 2003; 284: 2-13.
7. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004; 10: 5367-74.
8. Han C, Ma J, Zhao J, et al. EGFR mutations, gene amplification, and protein expression and KRAS mutations in primary and metastatic tumors of nonsmall cell lung cancers and their clinical implications: a meta-analysis. Cancer Invest 2011; 29: 626-34.
9. Banerji S, Cibulskis K, Rangel-Escareno C, et al. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 2012; 486: 405-9.
10. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490: 61-70.
11. Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 2012; 486: 353-60.
12. Borrell-Pages M, Rojo F, Albanell J, et al. TACE is required for the activation of the EGFR by TGF-[alpha] in tumors. EMBO J 2003; 22: 1114-24.
13. Kenny PA, Bissell MJ,. Targeting TACE-dependent EGFR ligand shedding in breast cancer. J Clin Invest 2007; 117: 337-45.
14. Briand P, Petersen OW, Van Deurs B,. A new diploid nontumorigenic human breast epithelial cell line isolated and propagated in chemically defined medium. In Vitro Cell Dev Biol 1987; 23: 181-8.
15. Moyret C, Madsen MW, Cooke J, et al. Gradual selection of a cellular clone presenting a mutation at codon 179 of the p53 gene during establishment of the immortalized human breast epithelial cell line HMT-3522. Exp Cell Res 1994; 215: 380-5.
16. Lee GY, Kenny PA, Lee EH, et al. Three-dimensional culture models of normal and malignant breast epithelial cells. Nat Methods 2007; 4: 359-65.
17. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347: 1999-2009.
18. Kenny PA, Lee GY, Myers CA, et al. The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression. Mol Oncol 2007; 1: 84-96.
19. McGowan PM, Mullooly M, Caiazza F, et al. ADAM-17: a novel therapeutic target for triple negative breast cancer. Ann Oncol 2013; 24: 362-9.
20. Kenny PA,. Three-dimensional extracellular matrix culture models of EGFR signalling and drug response. Biochem Soc Trans 2007; 35: 665-8.
21. Page-McCaw A, Ewald AJ, Werb Z,. Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol 2007; 8: 221-33.
22. Sahin U, Weskamp G, Kelly K, et al. Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands. J Cell Biol 2004; 164: 769-79.
23. Peschon JJ, Slack JL, Reddy P, et al. An essential role for ectodomain shedding in mammalian development. Science 1998; 282: 1281-4.
24. Luetteke NC, Qiu TH, Peiffer RL, et al. TGF alpha deficiency results in hair follicle and eye abnormalities in targeted and waved-1 mice. Cell 1993; 73: 263-78.
25. Wolf K, Friedl P,. Extracellular matrix determinants of proteolytic and non-proteolytic cell migration. Trends Cell Biol 2011; 21: 736-44.
26. Rodriguez D, Morrison CJ, Overall CM,. Matrix metalloproteinases: what do they not do? New substrates and biological roles identified by murine models and proteomics. Biochim Biophys Acta 2010; 1803: 39-54.
27. Baselga J, Albanell J, Ruiz A, et al. Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. J Clin Oncol 2005; 23: 5323-33.
28. Dickler MN, Rugo HS, Eberle CA, et al. A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer. Clin Cancer Res 2008; 14: 7878-83.
29. Gelmon K, Dent R, Mackey JR, et al. Targeting triple-negative breast cancer: optimising therapeutic outcomes. Ann Oncol 2012; 23: 2223-34.
30. Tabernero J, Cervantes A, Rivera F, et al. Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study. J Clin Oncol 2010; 28: 1181-9.
31. Infante J, Burris HA, Lewis N, et al. A multicenter phase Ib study of the safety, pharmacokinetics, biological activity and clinical efficacy of INCB7839, a potent and selective inhibitor of ADAM10 and ADAM17. Breast Cancer Res Treat 2007; 106: S269.
32. Newton R, Bradley E, Levy R, et al. Clinical benefit of INCB7839, a potent and selective ADAM inhibitor, in combination with trastuzumab in patients with metastatic HER2+ breast cancer. J Clin Oncol 2010; 28: 3025.
33. Yamamoto K, Trad A, Baumgart A, et al. A novel bispecific single-chain antibody for ADAM17 and CD3 induces T-cell-mediated lysis of prostate cancer cells. Biochem J 2012; 445: 135-44.